Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation

Goichi Yoshimoto, Yasuo Mori, Koji Kato, Jun Odawara, Takuro Kuriyama, Toshiyuki Ueno, Teppei Obara, Ayano Yurino, Shuro Yoshida, Ryosuke Ogawa, Yuju Ohno, Hiromi Iwasaki, Tetsuya Eto, Koichi Akashi, Toshihiro Miyamoto

Research output: Contribution to journalArticlepeer-review

Abstract

We retrospectively analyzed 38 patients with AML who received azacitidine (AZA) to treat disease relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients with objective response (OR) (n = 20) after AZA had significantly higher 2-year overall survival (OS) (45.0% vs 5.6%; p = 0.004) than progressive disease. The 2-year OS was significantly higher in the retransplant group (n = 23) than in the nonretransplant group (n = 15) (34.8% vs 13.3%; p = 0.034). We analyzed 167 patients who underwent the second allo-HSCT to clarify the impact of pretransplant AZA after the second allo-HSCT. Patients in the AZA group (n = 21) had significantly higher 2-year disease-free survival (DFS) (32.7% vs 14.5%; p = 0.012) and OS (38.1% vs 17.5%; p = 0.044) than those in the SOC group (n = 146). Our data demonstrate that AZA is an effective and well-tolerated bridging therapy to the second allo-HSCT.

Original languageEnglish
JournalLeukemia and Lymphoma
DOIs
Publication statusAccepted/In press - 2021

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation'. Together they form a unique fingerprint.

Cite this